Repare Therapeutics Inc (RPTX)
$3.47
+0.04
(+1.17%)▲
Live
Performance
- $3.33$3.55$3.47
4.03%
Downside
Day's Volatility :6.23%
Upside
2.29%
- $2.71$8.49$3.47
21.9%
Downside
52 Weeks Volatility :68.08%
Upside
59.13%
Returns
| Period | Repare Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -11.83% | 3.6% | 0.0% |
6 Months | 5.21% | 10.2% | 0.0% |
1 Year | -13.16% | 19.6% | 0.0% |
3 Years | -84.93% | 16.8% | -23.0% |
Highlights
Market Capitalization | 142.2M |
Book Value | $4.80 |
Earnings Per Share (EPS) | -1.63 |
Wall Street Target Price | 13.71 |
Profit Margin | -99.76% |
Operating Margin TTM | -3478.01% |
Return On Assets TTM | -22.3% |
Return On Equity TTM | -30.52% |
Revenue TTM | 68.7M |
Revenue Per Share TTM | 1.63 |
Quarterly Revenue Growth YOY | -96.5% |
Gross Profit TTM | 15.1M |
EBITDA | -93.8M |
Diluted Eps TTM | -1.63 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.22 |
EPS Estimate Next Year | -3.18 |
EPS Estimate Current Quarter | -0.87 |
EPS Estimate Next Quarter | -0.88 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 295.1%
Technicals Summary
Sell
Neutral
Buy
Repare Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Repare Therapeutics Inc | 1.48% | 5.21% | -13.16% | -84.93% | -88.86% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Repare Therapeutics Inc | NA | NA | NA | -2.22 | -0.31 | -0.22 | NA | 4.8 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Repare Therapeutics Inc | Buy | $142.2M | -88.86% | NA | -99.76% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Repare Therapeutics Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 52.40M → 1.07M (in $), with an average decrease of 98.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 13.16M → -34.77M (in $), with an average decrease of 364.2% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 104.0%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 129.7%
Institutional Holdings
Bvf Inc
24.35%Blue Owl Capital Holdings LP
7.95%Orbimed Advisors, LLC
7.83%Versant Venture Management LLC
6.24%ARK Investment Management LLC
6.20%Mpm Asset Management, LLC
5.28%
Company Information
repare therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. its approach integrates insights from several fields of cell biology including dna repair and synthetic lethality. repare’s platform combines a proprietary, high throughput, crispr‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics. the company is backed by leading global healthcare investors including founding investor versant ventures and mpm capital. for additional information, please visit www.reparerx.com.
Organization | Repare Therapeutics Inc |
Employees | 179 |
CEO | Mr. Lloyd Mitchell Segal |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$3.47
+1.17%
Invesco Bulletshares 2025 Hi
$3.47
+1.17%
Schwab International Dividend Equity Etf
$3.47
+1.17%
Blockchain Coinvestors Acquisition Corp.
$3.47
+1.17%
Allgiant Travel Company
$3.47
+1.17%
Rogers Corp
$3.47
+1.17%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$3.47
+1.17%
Iheartmedia
$3.47
+1.17%
Lightpath Technologies Inc
$3.47
+1.17%